Abstract
Sphingosine kinases (Sphk1 and 2) regulate the prodution of sphingosine-1-phosphate (S1P), that is key molecule in cancer development. SphK1, which is commonly overexpressed in malignant tumours, significantly contributes to the pathogenesis of various types of cancer as well as to resistance to different Tyrosine Kinase inibitors (TKIs). Even, SphK2 may promote apoptosis and inhibit cell growth but its role has not yet been fully understood in pathologic conditions. Different growth factorsinduced activation of receptor tyrosine kinases (RTKs) results in production of Sphk1 which catalyzes the phosphorylation of sphingosine. Such enzyme, in turn, is involved in many cellular processes by its five receptors. These are able to transactivate RTKs through amplification of a positive-feedback signaling loop. In conclusion, development of pharmacological inhibitors of SphK1 has been limited by the lack of completely understanding of the enzymatic activation mechanisms of SphK1.
Keywords: Cancer, receptor tyrosine kinases (RTKs), sphingosine kinase 1 (SphK1), sphingolipids, sphingosine 1-phosphate (S1P), tyrosine kinase inibitors (TKIs).
Mini-Reviews in Medicinal Chemistry
Title:Sphingosine Kinases Signalling in Carcinogenesis
Volume: 15 Issue: 4
Author(s): Gabriella Marfe, Giovanna Mirone, Arvind Shukla and Carla Di Stefano
Affiliation:
Keywords: Cancer, receptor tyrosine kinases (RTKs), sphingosine kinase 1 (SphK1), sphingolipids, sphingosine 1-phosphate (S1P), tyrosine kinase inibitors (TKIs).
Abstract: Sphingosine kinases (Sphk1 and 2) regulate the prodution of sphingosine-1-phosphate (S1P), that is key molecule in cancer development. SphK1, which is commonly overexpressed in malignant tumours, significantly contributes to the pathogenesis of various types of cancer as well as to resistance to different Tyrosine Kinase inibitors (TKIs). Even, SphK2 may promote apoptosis and inhibit cell growth but its role has not yet been fully understood in pathologic conditions. Different growth factorsinduced activation of receptor tyrosine kinases (RTKs) results in production of Sphk1 which catalyzes the phosphorylation of sphingosine. Such enzyme, in turn, is involved in many cellular processes by its five receptors. These are able to transactivate RTKs through amplification of a positive-feedback signaling loop. In conclusion, development of pharmacological inhibitors of SphK1 has been limited by the lack of completely understanding of the enzymatic activation mechanisms of SphK1.
Export Options
About this article
Cite this article as:
Marfe Gabriella, Mirone Giovanna, Shukla Arvind and Di Stefano Carla, Sphingosine Kinases Signalling in Carcinogenesis, Mini-Reviews in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1389557515666150227105415
DOI https://dx.doi.org/10.2174/1389557515666150227105415 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Function in Pregnant Women with Affective Disorders
Current Psychiatry Reviews Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Leptin as Clinical Target
Recent Patents on Inflammation & Allergy Drug Discovery The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Implication of CYP24A1 Splicing in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer in the Personal Genomics Era
Current Genomics A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Improved Drug Delivery System for Cancer Treatment by D-Glucose Conjugation with Eugenol From Natural Product
Current Drug Delivery PTEN, Insulin Resistance and Cancer
Current Pharmaceutical Design Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design Killing Glioma ‘Stem-like’ Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins
Anti-Cancer Agents in Medicinal Chemistry Synthesis and In vitro/In vivo Characterization of Raloxifene Grafted Poly(Styrene Maleic Acid)-Poly(Amide-Ether-Ester-Imide) Micelles for Targeted Delivery of Docetaxel in G Protein-Coupled Estrogen Receptor Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy MicroRNAs for Diagnosis and Treatment of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer Diagnosis Through IsomiR Expression with Machine Learning Method
Current Bioinformatics Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies
Current Cancer Therapy Reviews